Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 11/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.41 |
| ▸ | HTR4 | Q13639 | 9/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2127620 | 0.89 | HCRTR1 (0.46) | HCRTR1HCRTR2 | |
| SCHEMBL2127224 | 0.89 | HCRTR1 (0.40) | HCRTR1HCRTR2 | |
| SCHEMBL2128188 | 0.89 | HCRTR1 (0.37) | HCRTR1HCRTR2 | |
| SCHEMBL1571956 | 0.86 | HCRTR1 (0.47) | HCRTR1HCRTR2HTR4 | |
| SCHEMBL2125907 | 0.85 | HCRTR1 (0.38) | HCRTR1HCRTR2 | |
| SCHEMBL1338803 | 0.85 | HCRTR1 (0.45) | HCRTR1HCRTR2HTR4 | |
| SCHEMBL986632 | 0.85 | HCRTR1 (0.52) | HCRTR1HCRTR2 | |
| SCHEMBL2126694 | 0.84 | HCRTR1 (0.57) | HCRTR1HCRTR2 | |
| SCHEMBL2126629 | 0.84 | HCRTR1 (0.64) | HCRTR1HCRTR2 | |
| SCHEMBL983476 | 0.83 | HCRTR1 (0.55) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247586-B1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-04-25 | — | — | EP | claimed |
| US-20110009401-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-01-13 | — | — | US | claimed |
| EP-2247586-B1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-04-25 | — | — | EP | disclosed |
| US-20110009401-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009401-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | HCRTR2, HCRTR1, HCAR2 | HCRTR1 2/4885HCRTR2 1/4885HTR4 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.